Navigation Links
Recent Research Reports and Near-Term Corporate Events
Date:2/6/2008

LARGO, Fla., Feb. 6 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) (the "Company") announced today in an effort to communicate its story to as wide of an audience as possible it has placed both of the recent research reports issued about the company on its website at http://www.GeoPharmainc.com under the "Analyst Coverage" tab in the "For Investors" section and that it will be speaking publicly several times in the next few months.

In the most recent research report issued by Andre Garnet of Red Chip, a one year price target of $8 per share was established.

Additionally, GeoPharma has a speaking engagement at the Red Chip Small Cap Investor Conference in Scottsdale, AZ on Thursday, February 7th at 10:10 AM MST.

For those unable to attend in person, the presentation may be viewed online by logging in to the following site: http://www.visualwebcaster.com/event.asp?id=45650.

Speaking about GeoPharma, Red Chip President David Gentry remarked, "GeoPharma is one of the most compelling small cap stories I have seen and is exactly the type of fast growing undervalued situation the retail and institutional clientele that attend our conferences find attractive."

GeoPharma will also be an attending presenter at the Spring EdgeWater Research Partners conference being held at the Grand Hyatt in Denver, Colorado on April 8, 2008. EdgeWater, an Independent research organization and subscription based newsletter just recently issued a research report of its own on GeoPharma, formulating a price target of $7.25 with an 18-24 month time horizon.

Commenting on GeoPharma, EdgeWater Research analyst and publisher Dave Lavigne stated, "GeoPharma's story is just starting to unfold; we are pleased to have them join us at the spring conference in April to communicate their most recent developments."

Furthermore, GeoPharma has announced that it plans to release its 3rd quarter earnings report prior to trading on Thursday, February 14, 2008. A conference call hosted by GeoPharma CEO Mihir Taneja and GeoPharma CFO Carol Dore-Falcone at 11:30 EST will be held the same day. Anyone wishing to listen to the live call may do so by dialing 1-888-680-0869 using pass code 78555682 at 11:25 am EST.

A replay of the call will also be available from 1:30 PM February 14th through the 21st by dialing 1-888-286-8010 pass code 37538422. A webcast of the conference call will also be available on the GeoPharma website.

About GeoPharma, Inc:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the "For Investors" section of the GeoPharma website at http://www.geopharmainc.com.

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
2. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
3. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
4. ReBuilder Medical Technologies, Inc.s Recent Stock Price Volatility Explained
5. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
6. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
7. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
8. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
9. Access Highlighted in Recent BusinessWeek Article
10. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
11. Xenon Announces Appointment of VP, Discovery Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition Corporation , ... two more sessions of its “From the Helm” Webinar Series. , The ... online templates for design control exercises. Led by David Cronin, Cognition’s CEO, the ...
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
(Date:6/15/2017)... ... 15, 2017 , ... Adam Equipment, a leading provider of ... lab workstation. The guide outlines the procedure in four simple steps, using comprehensive ... anti-vibration table, OIML/ASTM certified weights, and Adam DU specialized software. , A lab ...
(Date:6/14/2017)... USA – , ... ... June 14, 2017 -- Diagenode, a leading global provider ... has licensed a new technology specific for ChIP-sequencing from ... immunoprecipitation followed by sequencing (ChIP-seq) allows the study of ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):